Key result
COVID-19 mRNA vaccine-associated myopericarditis in adolescents and young adults was associated with a 92.6% hospitalization rate and 23.2% ICU admission rate, but 0% in-hospital mortality.
Why the study?
Data on COVID-19 mRNA vaccine-associated myopericarditis in adolescents and young adults were limited to small series or passive systems, with pooled evidence from large international cohorts lacking.
Population
854 adolescents and young adults aged 12 to 20 years across 23 observational studies
Design
Systematic review and one-group random-effects meta-analysis
Authors
Loading...
High hospitalization/ICU rates warrant vigilant monitoring post-vaccination in youth; leaves open long-term cardiac outcomes.
Meta-Analysis (n=854)
Yes
COVID-19 mRNA vaccine-associated myopericarditis in adolescents and young adults has a largely favorable early clinical course with no reported deaths, despite frequent hospitalization and ICU admission.
Yasuhara et al. (2022) conducted a meta-analysis in COVID-19 vaccine-associated myopericarditis (n=854). COVID-19 mRNA vaccination was evaluated on clinical features and early outcomes for COVID-19 mRNA vaccine-associated myopericarditis, including incident rate, cardiac findings, hospitalization, intensive care unit (ICU) admission, and in-hospital mortality. COVID-19 mRNA vaccine-associated myopericarditis in adolescents and young adults was associated with a 92.6% hospitalization rate and 23.2% ICU admission rate, but 0% in-hospital mortality.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: